BioMedNewsBreaks

ThursdayOct 19, 2023 12:34 pm

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Spotlighted in Latest Episode of Bell2Bell Podcast

PaxMedica (NASDAQ: PXMD), a prominent clinical-stage biopharmaceutical company, was featured in the most recent release of the Bell2Bell podcast series. During the segment, PaxMedia CEO and chair Howard Weisman and PaxMedica corporate communications representative Buzz Woods provided an overview of the company’s latest accomplishments and future objectives with Bell2Bell host Stuart Smith. The trio discussed PaxMedia’s pioneering work in novel anti-purinergic drug therapies (“APT”) for neurologic conditions, specifically autism spectrum disorder (“ASD”) along with the company’s initiatives and visionary advancements in the novel APT therapies space. The Bell2Bell Podcast is part of IBN’s sustained effort to provide specialized content distribution via widespread…

Continue Reading

WednesdayOct 18, 2023 1:33 pm

BioMedNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Featured in Bell2Bell Podcast

PaxMedica (NASDAQ: PXMD), a prominent clinical-stage biopharmaceutical firm, was featured in the latest episode of the Bell2Bell Podcast, a part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. PaxMedica’s CEO and Chairman Howard Weisman and Buzz Woods, from the company’s corporate communications department, joined the program to offer a compelling overview of the company’s recent achievements and future objectives. During the podcast, Weisman and Woods share insights into the company’s groundbreaking work in novel anti-purinergic drug therapies (“APT”) for neurologic conditions, primarily autism spectrum disorder (“ASD”). They discuss perspectives on PaxMedica’s initiatives and visionary advancements…

Continue Reading

WednesdayOct 18, 2023 9:53 am

BioMedNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Strengthen Position in Alternative Mental-Health Treatments Sector

Lucy Scientific Discovery (NASDAQ: LSDI), a pioneer in alternative mental-health treatments, is working to provide ingredients for effective mental-health treatment and therapies, including psilocybin and MDMA. According to a recent article spotlighting LSDI, the company is “well positioned” to support the mental-health space as it continues to grow. The article noted that mental-health issues are impacting millions of Americans a year and that treatments are finally evolving to treat these issues. Prescriptions for selective serotonin reuptake inhibitors (“SSRIs”) have long been a mainstay in the industry, but they don’t work for everyone and often have debilitating side effects. The article…

Continue Reading

TuesdayOct 17, 2023 11:44 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) ‘Innovates’ Investigational Drug with Patented Nanotechnology

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, announced that it has innovated its investigational drug, CNM-Au8(R), with nanotechnology. Clene is evaluating CNM-Au8(R) for the treatment of neurodegenerative disease, and the innovation reflects the growing importance of nanotechnology in the drug space. The announcement noted that Clene’s nanotechnological approach was recently awarded a substantial grant by the National Institute of Neurological Disorders and Stroke (“NINDS”) of the National Institutes of Health (“NIH”) to conduct an Expanded Access Protocol in ALS. The announcement also noted that Clene is…

Continue Reading

MondayOct 16, 2023 12:37 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Innovative Glioblastoma Treatment ‘Could Offer Hope’

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is spotlighted in a recent article focused on glioblastoma, the most aggressive type of brain cancer. Noting that glioblastoma has an average survival of only 14 to 16 months after diagnosis, the article points out that currently, glioblastoma has no cure and, because it is a highly invasive tumor, complete surgical removal is difficult. “Even with aggressive treatment, the cancer tends to recur, leading to a grim prognosis,” the article states. “The high mortality rate of…

Continue Reading

MondayOct 16, 2023 12:09 pm

BioMedNewsBreaks – Safety Shot (NASDAQ: SHOT) Announces MMA Superstar Jorge “Gamebred” Masvidal as Brand Ambassador

Safety Shot (NASDAQ: SHOT), a wellness and functional beverage company, has sealed a deal with mixed martial arts (“MMA”) superstar Jorge Masvidal. The agreement calls for Masvidal to serve as brand ambassador for Safety Shot, the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity. Safety Shot announced that agreement after becoming a ring sponsor for Gamebred Bareknuckle MMA matches. An MMA superstar, Masvidal has competed professionally for two decades, including a bout for the Ultimate Fighting Championship (“UFC”), where won the championship belt and knocked out his opponent in…

Continue Reading

MondayOct 16, 2023 11:21 am

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Closes on $4M Registered Direct Offering

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, closed on its previously announced registered direct offering. The offering was comprised of 2,424,243 shares of Class A common stock or common stock equivalents priced at $1.65 per share, or common stock equivalent. In addition, Longeveron issued unregistered Series A warrants in a concurrent private placement; the private placement included 2,424,243 shares of LGVN common stock and unregistered Series B warrants. The warrants, which have an exercise price of $1.65 per share, are…

Continue Reading

FridayOct 13, 2023 2:27 pm

BioMedNewsBreaks — Octane Selects IBN as Official Media Partner for Upcoming Medical Innovation Forum

Octane, a convening organization of the Southern California technology and medical technology business ecosystem, is partnering with IBN (“InvestorBrandNetwork”), a pioneering corporate communications firm and content distributor, to provide key communications and coverage of Octane’s Medical Innovation Forum. According to the announcement, IBN will serve as Official Media Partner for the event, with IBN’s InvestorWire serving as the Official NewsWire. The two-day forum is slated for Oct. 25–26, 2023, in Irvine, California. Octane is committed to create and support a thriving business ecosystem in Southern California by fostering the growth of tech and medtech ventures; the organization has a goal of…

Continue Reading

ThursdayOct 12, 2023 3:48 pm

BioMedNewsBreaks – NextPlat Corp. (NASDAQ: NXPL) Announces Launch of OPKO Health Inc. (NASDAQ: OPK)-Branded Online Storefront

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, today announced that, through a new e-commerce distribution agreement, it will enable the online sales of OPKO Health Europe, a subsidiary of OPKO Health (NASDAQ: OPK) products in China. Under the agreement terms, NextPlat will launch a OPKO Health-branded online storefront on Alibaba Group Holding Limited's (NYSE: BABA) Tmall Global e-commerce platform in China featuring an assortment of nutraceutical and veterinary products sold and distributed by OPKO Europe. “NextPlat’s focus is to enable companies across an array of high-growth sectors, such as health care and consumer products, to capitalize on the vast…

Continue Reading

ThursdayOct 12, 2023 1:36 pm

BioMedNewsBreaks – Octane’s Upcoming Forum to Feature Visionaries, Cutting-Edge Advances in Medical Technology Space

Octane, a strategic partner for emerging companies, today announced details of this year’s Octane 2023 Medical Innovation Forum. The two-day event is slated to take place at the Irvine Marriott in Irvine, California, on October 25-26, 2023. The forum will feature some of the medical technology sector’s most visionary speakers, granting access to invaluable educational opportunities, showcasing cutting-edge technological advances, and providing a prime networking platform to explore synergies and foster enduring partnerships among industry professionals. “Southern California is one of the country’s most dynamic and promising markets, and Octane aims to create more than 55,000 technology jobs by 2030…

Continue Reading